Group 1 - The A-share market experienced a rebound in the second quarter, with the Shanghai Composite Index briefly surpassing 3600 points, driven by themes such as AI, new consumption, and innovative pharmaceuticals [1] - Major active equity fund managers, who had faced several years of downturn, saw a collective performance recovery in the second quarter, marking a critical moment to validate their investment philosophies [1] Group 2 - Among active equity funds with over 10 billion yuan, the top performer was the China Europe Medical Health A fund, managed by Zhao Lei and Ge Lan, achieving a year-to-date return of 28.07% [2] - The second-best performer, Xingquan He Yi A, managed by Xie Zhiyu and Xie Zhiyu, recorded a return of 24.70%, attributed to a shift in investment focus towards technology and pharmaceutical growth stocks [2][3] - Ruiyuan Growth Value A, managed by Zhu Lin and Fu Pengbo, ranked third with over 20% growth, focusing on electronic, internet technology, precision manufacturing, and pharmaceuticals [4] Group 3 - Ge Lan expressed optimism about the pharmaceutical sector, citing supportive policy environments and the expansion of commercial health insurance as factors that enhance the payment capacity for innovative drugs [3] - Xie Zhiyu's investment strategy included increasing holdings in innovative pharmaceutical companies listed in Hong Kong, which saw significant price increases in the second quarter [3] - Fu Pengbo noted a structural adjustment in his portfolio, increasing exposure to the PCB industry while reducing traditional energy stocks, indicating a proactive approach to market changes [4]

Investment Rating - The report maintains an "Outperform" rating for multiple leading innovative drug companies and CXOs in the healthcare sector [2]. Core Insights - The report emphasizes a sustained positive outlook on the innovative drug industry and its supply chain, highlighting the importance of increasing allocations to leading companies in this space [4][6]. - The performance of the Hong Kong stock picks portfolio showed an average increase of 27.1% in July 2025, outperforming the Hang Seng Healthcare Index, which rose by 22.8% [5][9]. - Major business development (BD) and merger & acquisition (M&A) activities in the innovative drug sector are ongoing, with significant deals reported, indicating a robust market environment [6][35][36]. Summary by Sections Investment Focus - The report lists several companies with an "Outperform" rating, including 恒瑞医药 (Hengrui Pharmaceuticals), 迈瑞医疗 (Mindray), 药明康德 (WuXi AppTec), and others [2]. Performance Analysis - The July 2025 Hong Kong stock picks portfolio included companies like 信达生物 (Innovent Biologics) and 百济神州 (BeiGene), with top performers showing significant gains, such as 映恩生物 (DualityBio) at +48.0% [5][10]. - The healthcare sector in Hong Kong saw notable gains, with companies like 华检医疗 (IVD Medical) and 加科思-B (Jacobio Pharmaceuticals) leading the way [6][34]. Market Trends - The report highlights a recovery in the global innovative drug sector, with leading CXO firms like 药明合联 (WuXi XDC) and 药明康德 (WuXi AppTec) reporting strong earnings growth [7][37]. - Optimized centralized procurement policies and steady progress in innovative drug reimbursement are noted, with over 100 drugs applying for inclusion in the innovative drug reimbursement list [7][38][39]. Company-Specific Insights - 石药集团 (CSPC) and 中国生物制药 (Sino Biopharmaceutical) are newly added to the top picks, with strong potential in their respective innovative drug pipelines [4][32]. - The report discusses the promising clinical pipelines of companies like 三生制药 (3SBio) and 信达生物 (Innovent Biologics), indicating robust growth prospects [18][23].

Market Performance - The CSI Cloud Computing and Big Data Theme Index increased by 1.2% [1] - The CSI Artificial Intelligence Theme Index rose by 0.5% [1] - The National Robot Industry Index decreased by 0.3% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 1.2% [1] - The CSI New Energy Index dropped by 3.1% [1] Company Developments - Alibaba Health launched an AI medical assistant named "Hydrogen Atom," which integrates millions of core medical journal articles and supports authoritative guideline access, semantic search, AI summarization, full-text translation, and intelligent Q&A [1] - The AI assistant is designed to help clinical medical workers and researchers quickly find necessary information, enhancing medical learning and research efficiency [1] Index Overview - The Artificial Intelligence ETF tracks the CSI Artificial Intelligence Theme Index, which comprehensively covers the AI industry chain, including upstream infrastructure, midstream models, and downstream applications [2] - The Robot ETF tracks the National Robot Industry Index, which covers the entire robot industry chain, with humanoid robots making up 53% of the index [2] - The Cloud Computing ETF tracks the CSI Cloud Computing and Big Data Theme Index, focusing on the cloud computing industry and related services [3] - The Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which includes stocks involved in innovative drug research, development, and production [3] - The New Energy ETF tracks the CSI New Energy Index, covering the new energy industry chain, including lithium batteries, photovoltaics, wind power, hydropower, and nuclear power [3]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index, the CSI Innovative Drug Industry Index, and the CSI Biotechnology Theme Index all declined by 1.2%, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index fell by 1.3%, and the CSI 300 Medical and Health Index decreased by 2.1% [1] - As of yesterday, the Hang Seng Innovative Drug ETF (159316) has seen continuous inflows for 12 trading days, with its latest scale exceeding 900 million yuan, reaching a historical high [1] Group 2 - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which focuses on leading innovative drug companies in the Hong Kong stock market, composed of no more than 40 stocks involved in innovative drug research, development, and production [2] - The index has experienced a decline of 1.2% with a rolling P/E ratio of 35.3 times as of July 10, 2023 [2] - The Hong Kong Stock Connect Medical ETF tracks the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index, which focuses on leading companies in the medical and health sector, composed of 50 stocks from medical devices, biopharmaceuticals, and chemical drugs [2] - This index has also declined by 1.3% with a rolling P/E ratio of 33.5 times, and it has a valuation percentile of 50.7% since its inception in 2017 [2]

Market Performance - On July 31, 2025, the Shanghai Composite Index fell by 1.18%, the Shenzhen Component Index decreased by 1.73%, and the ChiNext Index dropped by 1.66%[2] - The total market turnover reached 1,916.18 billion yuan, an increase of 88.29 billion yuan compared to the previous trading day[2] - Out of 5,152 stocks, 1,019 rose while 4,133 declined[2] Sector and Style Analysis - Among the 30 sectors, the Computer sector showed a slight increase of 0.73%, while the Steel sector saw the largest decline at -3.79%[19] - Growth stocks outperformed value stocks, with small-cap growth leading the performance[19] Capital Flow - On July 31, 2025, the net outflow of main funds was 56.93 billion yuan, with large orders contributing to a significant portion of the outflow[23] - Small orders continued to see a net inflow of 67.14 billion yuan, indicating retail investor interest[23] ETF Activity - Major ETFs such as the Huaxia SSE 50 ETF and the Huatai-PB CSI 300 ETF saw increases in trading volume, with changes of +3.17 billion yuan and +6.64 billion yuan respectively[27] - The net inflow into the ChiNext ETF was 1.56 billion yuan on July 30, 2025, indicating a shift in investor focus towards growth sectors[27] Global Market Trends - On July 31, 2025, the Hang Seng Index fell by 1.60%, while the Nikkei 225 Index rose by 1.02%[31] - The U.S. stock market showed mixed results, with the Dow Jones Industrial Average down by 0.38% and the Nasdaq Composite up by 0.15%[32]

Core Insights - In July, southbound funds recorded a cumulative net inflow of 135.65 billion HKD, returning to a scale exceeding 100 billion after a slowdown in May and June [1][2] - Year-to-date, southbound funds have accumulated a total inflow of 866.84 billion HKD, surpassing the total inflow for the entire previous year, equivalent to 107% of the expected inflow for 2024 [2] Industry Analysis - Significant inflows were observed in the financial and healthcare sectors, with net purchases of 49.78 billion HKD and 22.25 billion HKD respectively, while consumer stocks saw substantial sell-offs [2][4] - The non-essential consumer sector experienced a net outflow of 31.54 billion HKD, indicating a decline in the "new consumption" concept [4] Market Performance - The Hang Seng Index rose by 2.91% in July, reaching new highs for the year, with total trading volume of 57.8 trillion HKD, the highest since April [5] - Southbound funds accounted for approximately 55% of the trading volume during the same period [5] Stock-Specific Movements - Major net inflows were recorded for Meituan (89.82 billion HKD), China Construction Bank (75.13 billion HKD), and SMIC (62.28 billion HKD) [6] - Significant net outflows were noted for Tencent Holdings (41.45 billion HKD), Pop Mart (26.77 billion HKD), and Xiaomi Group (18.51 billion HKD) [7] Recent Trends - Meituan saw a cumulative decline of 2.95% in July, with short-term funds primarily flowing out [8] - China Construction Bank and SMIC experienced gains of 1.64% and 14.32% respectively, with continued inflows [9][10] - China Life Insurance surged by 24%, attracting accelerated inflows [10] ETF Activity - Southbound funds significantly increased their positions in three major ETFs: the Tracker Fund of Hong Kong (24.05 billion HKD), Hang Seng China Enterprises (17.81 billion HKD), and Southern Hang Seng Technology (9.73 billion HKD) [15]

Market Overview - In July, the A-share market saw significant gains, with the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index rising by 3.74%, 5.2%, and 8.14% respectively [1] - The total market capitalization of A-shares reached 104.48 trillion yuan, an increase of 4.43 trillion yuan in a single month [1] Sector Performance - The steel industry was the best-performing sector in July, with a rise of 16.76%, followed by the pharmaceutical and biological sector at 13.93%, and building materials at 13.36% [2][3] - A total of 31 sectors saw positive performance, with only banking, utilities, and transportation sectors experiencing declines of 1.95%, 0.77%, and 0.22% respectively [2] Top Stocks - The top-performing stock in July was Upwind New Material, which saw an increase of over 1080%, including 11 instances of a "20CM" limit-up [1][4] - A total of 3640 stocks had positive returns, with 449 stocks rising over 20% and 84 stocks rising over 50% [4] Notable Stock Movements - Upwind New Material's market capitalization grew from 3.138 billion yuan to 37.14 billion yuan during July, following an announcement of a significant share acquisition by Zhiyuan Robotics [4] - The stock was subject to multiple trading suspensions due to abnormal price fluctuations [4] Future Outlook - Analysts from Everbright Securities suggest that A-share valuations remain attractive compared to risk-free rates, indicating potential for continued upward movement [5] - Huashan Securities emphasizes the importance of focusing on sectors with strong fundamentals and potential for exceeding performance expectations in the upcoming reporting season [5]

尾盘，再现异动！ 7月31日，A股三大指数集体调整，截至今日收盘，沪指下跌1.18%，深证成指跌1.73%，创业板指跌1.66%。从盘面上看，钢铁、煤 炭、有色等前期过热的板块集体大跌，AI、创新药概念股则逆市上涨。 值得关注的是，临近收盘时，创新医疗、爱朋医疗、三博脑科等多只脑机接口概念股直线拉升，创新医疗一度逼近涨停。从消息面来 看，当天下午，脑机接口板块迎来一则利好消息。据报道，国家医保局支持脑机接口等新技术进入临床并收费。 脑机接口概念股尾盘拉升 7月31日，临近A股尾盘时分，多只脑机接口概念股突然直线拉升，创新医疗涨幅一度达到9.62%，爱朋医疗一度涨超9%，三博脑科、 倍益康、熵基科技、南京熊猫等相关概念股均有拉升动作。 | 壳价 叠加 重播 统计 | | 分时 1分钟 5分钟 15分钟 30分钟 60分钟 日线 更多 > | | 画线 F10 | 标记 -自选 返回 | | 创新医疗 002173 | | | | 医疗保健 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 创新医疗 分时 ...

美联储9月能否降息主要取决于7-8月经济数据 华泰证券研报表示，鲍威尔讲话未能提供9月降息的指引，发言偏鹰派。基本面方面，鲍威尔强调就业 市场较为稳健（solid），但承认存在下行风险。利率指引方面，鲍威尔未对9月降息给出明确指引，强 调降息决策取决于后续数据。 往前看，美联储9月能否降息主要取决于7-8月经济数据。维持美联储仍 有可能在9-12月降息两次的判断。 但是，如果就业和通胀数据强于预期，美联储年内降息预期或进一 步回撤。近期关注周五（8月1日）将公布的新增非农就业数据。 免责声明 以上观点来自相关机构，不代表天天基金的观点，不对观点的准确性和完整性做任何保证。 收益率数据仅供参考，过往业绩和走势风格不预示未来表现，不构成投资建议。转引的相关 观点均来自相关机构或公开媒体渠道 不代表天天基金的观点 天天基金不对观点的准确性 GUIDE 摘要 中原证券：短期面临技术性调整压力，但中期上行趋势未改； 中信证券：A股增量市场确立，资金共识将聚焦两大方向 ； 华泰证券：美联储9月能否降息主要取决于7- 8月经济数据。 中原证券 短期面临技术性调整压力，但中期上行趋势未改 中原证券认为， 当前，A股市场已进入 ...

Group 1 - The stock price of Junshi Biosciences-U closed at 38.46 yuan on July 31, down 1.69% from the previous trading day [1] - The trading volume on that day reached 782 million yuan, with a turnover rate of 2.60% [1] - Junshi Biosciences-U is focused on the research, production, and commercialization of innovative drugs, with key products including Toripalimab, targeting oncology and autoimmune diseases [1] Group 2 - In 2025, the National Medical Products Administration has approved over 20 Class 1 innovative drugs for market launch, setting a record for the past five years [1] - There have been more than 50 licensing cooperation events for domestic innovative drugs going abroad, with a total disclosed cooperation amount exceeding 48.4 billion USD [1] - On July 31, the net outflow of main funds for Junshi Biosciences-U was 49.655 million yuan, accounting for 0.17% of the circulating market value [1]